Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells

Cancer Gene Therapy

Volumn 20, Issue 7, 2013, Pages 421-427

  Koldehoff, M ^a   Zakrzewski, J L ^b   Beelen, D W ^a   Elmaagacli, A H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Advanced leukemia; BCR ABL; GFI1B; K562; Small interfering RNA

Indexed keywords

BCR ABL PROTEIN; GROWTH FACTOR INDEPENDENT 1B PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; GENE MAPPING; GENE SILENCING; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; ONCOGENE MYC; PRIORITY JOURNAL;

APOPTOSIS; CELL PROLIFERATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MURINAE;

EID: 84880917451     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.31     Document Type: Article

References (33)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
2. Goldmann JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1461.
3. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
4. Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H. Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Differentiation 2008; 76: 908-922.
5. Lage H. Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 2005; 1: 103-113.
6. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498. (Pubitemid 32494397)
7. Elmaagacli AH, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen DW et al. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 2005; 90: 326-334. (Pubitemid 40388982)
8. Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 2010; 95: 388-397.
9. Tong B, Grimes HL, Ty Yang, Bear SE, Qin Z, Du K et al. The GFI1B protooncoprotein represses p21WAF1 and inhibits myloid cell differentation. Mol Cell Bio 1998; 18: 2462-2473.
10. Rodel B, Wagner T, Zornig M, Niessing J, Moroy T. The human homologue (GFI1B) of the chicken GFI gene maps to chromosome 9q34.13-A locus frequently altered in hematopoietic diseases. Genomics 1998; 54: 580-582. (Pubitemid 29036251)
11. Elmaagacli AH, Koldehoff M, Zakrzewski JL, Steckel NK, Ottinger H, Beelen DW. Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate. Br J Haematol 2007; 136: 212-219. (Pubitemid 46020748)
12. Vassen L, Khandanpour C, Ebeling P, van der Reijden BA, Jansen JH, Mahlmann S et al. Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int J Hematol 2009; 89: 422-430.
13. Koldehoff M, Zakrzewski JL, Klein-Hitpass L, Beelen DW, Elmaagacli AH. Gene profiling of growth factor independence 1B gene (GFI1B) in leukemic cells. Int J Hematol 2008; 87: 39-47.
14. Elmaagacli AH, Freist A, Hahn M, Opalka B, Seeber S, Schaefer SW et al. Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haematol 2001; 113: 1072-1075. (Pubitemid 32634778)
15. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffinembedded tumor tissue. Am J Pathol 2001; 158: 419-429. (Pubitemid 32158605)
16. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M et al. Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 2002; 87: 569-577. (Pubitemid 34640638)
17. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 2007; 86: 166-173. (Pubitemid 47425197)
18. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of BCR-ABL gene expression by small interfering RNA. Blood 2003; 101: 1566-1569. (Pubitemid 36182535)
19. Novina CD, Sharp PA. The RNAi revolution. Nature 2004; 430: 161-164. (Pubitemid 38902417)
20. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against BCR-ABL transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47-55. (Pubitemid 47036743)
21. Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J et al. Inhibition of BCR-ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003; 102: 2236-2269.
22. Wilda M, Fuchs U, Wo?ssmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference. Oncogene 2002; 21: 5716-5724.
23. Merkerova M, Klamova H, Brdicka R, Bruchova H. Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep 2007; 34: 27-33. (Pubitemid 46220354)
24. Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY. Targeting primary human leukaemia cells with RNA interference: BCR-ABL targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 2005; 129: 377-380. (Pubitemid 40646897)
25. Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods 2006; 3: 670-676. (Pubitemid 44275732)
26. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561-566.
27. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254-2264.
28. Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002; 21: 8577-8583. (Pubitemid 36084190)
29. Rumpold H, Webersinke G. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr Cancer Drug Targets 2011; 11: 3-19.
30. Schulz D, Vassen L, Chow KT, McWhirter SM, Amin RH, Mo? ro?y T et al. Gfi1b negatively regulates Rag expression directly and via the repression of FoxO1. J Exp Med 2012; 209: 187-199.
31. Ohba H, Zhelev Z, Bakalova R, Ewis A, Omori T, Ishikawa M et al. Inhibition of BCR-ABL and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes. Cancer 2004; 101: 1390-1403. (Pubitemid 39180395)
32. Crews LA, Jamieson CH. Chronic myeloid leukemia stem cell biology. Curr Hematol Malig Rep 2012; 7: 125-132.
33. Albajar M, Gómez-Casares MT, Llorca J, Mauleon I, Vaqué JP, Acosta JC et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res 2011; 9: 564-576.